(Q37937303)

25 August 2017

1 reference

title

The use of omega-3 fatty acids in mental illness (English)

1 reference

25 August 2017

0 references

Jessica L Gören

1

1 reference

25 August 2017

Ashley T Tewksbury

series ordinal

2

1 reference

25 August 2017

publication date

22 September 2011

1 reference

Journal of Pharmacy Practice

25 August 2017

published in

1 reference

25 August 2017

volume

24

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

452-471

1 reference

Understanding omega-3 polyunsaturated fatty acids

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Case-control study of breast cancer in south east England: nutritional factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

How do fish oils affect vascular function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acids from fish oils and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fish consumption and depressive symptoms in the general population in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fatty acid composition in major depression: decreased ω3 fractions in cholesteryl esters and increased C20:4ω6C20:5ω3 ratio in cholesteryl esters and phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fish and n-3 polyunsaturated fatty acid intake and depressive symptoms: Ryukyus Child Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Is low dietary intake of omega-3 fatty acids associated with depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 treatment of childhood depression: a controlled, double-blind pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Risk of postpartum depression in relation to dietary fish and fat intake in Japan: the Osaka Maternal and Child Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fish and long-chain n-3 polyunsaturated fatty acid intakes during pregnancy and risk of postpartum depression: a prospective study based on a large national birth cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Mood-stabilizers target the brain arachidonic acid cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Regulation of brain polyunsaturated fatty acid uptake and turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Cross-national comparisons of seafood consumption and rates of bipolar disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Polyunsaturated fatty acid deficit in patients with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Brain lipid concentrations in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 Eicosapentaenoic Acid in Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acids in bipolar disorder: clinical and research considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Clinical potential of omega-3 fatty acids in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

The membrane hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fat consumption and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acid status in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acids in boys with behavior, learning, and health problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

The effect of fish oil on physical aggression in schoolchildren--a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Qualitative or Quantitative Differences Between Asperger’s Disorder and Autism? Historical Considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A prospective study of the emergence of early behavioral signs of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Factors associated with age of diagnosis among children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Could oxidative stress be a factor in neurodevelopmental disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Inhibition of neuronal apoptosis by polyunsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Effects of docosapentaenoic acid on neuronal apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Reduced numbers of dopamine neurons in the substantia nigra pars compacta and ventral tegmental area of rats fed an n-3 polyunsaturated fatty acid-deficient diet: a stereological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Modulation of response to environmental stimulation in autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Autistic symptoms in children with attention deficit-hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Frequency of symptoms of attention deficit and hyperactivity disorder in autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Plasma fatty acid levels in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Plasma fatty acid profiles in autism: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Essential fatty acids and phospholipase A2 in autistic spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Fatty acid compositions of red blood cell phospholipids in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega 3 fatty acid treatment in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Role of polyunsaturated fatty acids in the management of Egyptian children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Vitamin E and omega-3 fatty acids: effectors of platelet responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Mixture of essential fatty acids lowers test anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Psychopharmacology in autism: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

A placebo-controlled cross-over trial of adjunctive EPA in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Possible deleterious effects of adjunctive omega-3 fatty acids in post-traumatic stress disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Persistent organic pollutants at the base of the Antarctic marine food web.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

Reduction of organochlorine contaminants from fish oil during refining.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190011422876

21 January 2018

Identifiers

DOI

10.1177/0897190011422876

1 reference

25 August 2017

1 reference